The global point-of-care infectious disease diagnostics market size is estimated at USD 5.36 billion in 2024, grew to USD 6.20 billion in 2025 and is predicted to surpass around USD 22.86 billion by 2034, expanding at a CAGR of 15.60% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Point-of-Care Infectious Disease Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Point-of-Care Infectious Disease Diagnostics Market, by Technology, 2024-2034
8.1.1 Lateral Flow
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Agglutination Assays
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Flow Through
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Solid Phase
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Point-of-Care Infectious Disease Diagnostics Market, by Application, 2024-2034
9.1.1. HIV
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Liver Disease
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Tropical Disease
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Inflammatory Disease
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Respiratory Disease
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Hospital Associated Infections (HAIs)
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Sexual Health Disorders
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2021-2034)
10.1. Point-of-Care Infectious Disease Diagnostics Market, by End-user, 2024-2034
10.1.1. Hospital
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Home-care settings
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by End-user (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-user (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-user (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by End-user (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-user (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-user (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-user (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-user (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by End-user (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-user (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-user (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-user (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-user (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by End-user (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-user (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-user (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-user (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-user (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by End-user (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-user (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-user (2021-2034)
12.1. Danaher Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Alcon Laboratories, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott Laboratories
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Hoffman- La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Becton, Dickinson and Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Trinity Biotech Plc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Cardinal Health Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample